Novartis signs cancer immunotherapy deal with Penn
R&D alliance with the University of Pennsylvania will focus on novel T-cell immunotherapies
Read More
Section: Research
Astellas to close US urology research facility
Work at Urogenix, North Carolina site will end by the end of the year
Read MoreBoehringer to manufacture Servier’s gevokizumab
Will produce inflammatory disease drug at its Biberach facility
Read More
BMS halts trial of hepatitis C drug on safety issues
At least one person in study thought to have developed congestive heart failure
Read More
Pfizer sells Kent R&D centre to property consortium
Discovery Park Ltd takes over site 18 months after US pharma firm announced plans to exit it
Read More